JP5254227B2 - ケルセチン含有組成物 - Google Patents
ケルセチン含有組成物 Download PDFInfo
- Publication number
- JP5254227B2 JP5254227B2 JP2009520941A JP2009520941A JP5254227B2 JP 5254227 B2 JP5254227 B2 JP 5254227B2 JP 2009520941 A JP2009520941 A JP 2009520941A JP 2009520941 A JP2009520941 A JP 2009520941A JP 5254227 B2 JP5254227 B2 JP 5254227B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- quercetin
- vitamin
- composition according
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
Description
ケルセチンなどの天然の抗酸化剤のいくつかは、急性期および慢性期のフリーラジカル誘発性疾患を抑制することが知られている。さらに、ある天然抗酸化剤は、たとえば、ヒドロキシラジカル、超酸化物、一酸化硫黄、二酸化硫黄、および二酸化窒素のような生体関連酸素種との反応において、相乗効果をしめす。
本発明の実施形態として、ケルセチン、ビタミンB3、およびビタミンCを含有し、ケルセチン、ビタミンB3、およびビタミンCの重量比が、1:0.02〜1:0.2〜2.5である組成物であることを特徴とする。
本発明は、少なくともある部分は、活性成分としてケルセチン、ビタミンB3、およびビタミンCを含む組成物が健康への相乗的有益性を示し、対象者の身体的または精神的能力を増強するが、その上、経口投与において、ケルセチン単独に比べてケルセチン、ビタミンB3、およびビタミンCの組み合わせにより、血漿中のケルセチン濃度が著しく高くなるという、予期しなかった発見に基づいている。さらに関連して驚くべきことに、ケルセチン単独またはケルセチンおよびビタミンB3の組み合わせに比べ、ケルセチン、ビタミンB3、およびビタミンCの組み合わせは血漿中のケルセチン濃度を5倍まで高く維持できる。また、ケルセチン、ビタミンB3、およびビタミンCの組み合わせた場合の血漿中のケルセチンの半減期は、ケルセチン単独の2倍、並びにケルセチンおよびビタミンB3の組み合わせの約1.5倍もの長い半減期を示す。
(他の実施形態)
本明細書に開示されたすべての特徴は、任意の組み合わせで組み合わせられうる。本明細書に開示されたそれぞれの特徴は、同一の、等価な、または類似の目的に資する他の特徴により置換されうる。よって、そうでないと明記しない限り、開示されたそれぞれの特徴は、等価な、または類似の上位概念の一連の特徴の例示にすぎない。
Claims (17)
- 活性成分としてケルセチン、ビタミンB3、およびビタミンCのみを含み、ケルセチン、ビタミンB3、およびビタミンCの重量比が、1:0.02〜1:0.2〜2.5である組成物。
- 前記重量比が、1:0.05〜0.2:0.5〜1であることを特徴とする、請求項1に記載の組成物。
- 前記重量比が、1:0.1〜0.2:0.5〜1であることを特徴とする、請求項1に記載の組成物。
- 前記重量比が、1:0.04:1であることを特徴とする、請求項1に記載の組成物。
- 前記重量比が、1:0.08:1であることを特徴とする、請求項1に記載の組成物。
- 乾燥体である、請求項1〜5のいずれか1項に記載の組成物。
- 液体である、請求項1〜5のいずれか1項に記載の組成物。
- 食品である、請求項1〜7のいずれか1項に記載の組成物。
- 食品が、茶、清涼飲料、ジュース、牛乳、コーヒー、ゼリー、アイスクリーム、ヨーグルト、クッキー、シリアル、チョコレート、またはスナック菓子である、請求項8に記載の組成物。
- 組成物がダイエット用サプリメント、または医薬用製剤である、請求項1〜7のいずれか1項に記載の組成物。
- 組成物が錠剤、カプセル剤、ソフト剤、ゲル剤である、請求項10記載の組成物。
- ケルセチン、ビタミンB3およびビタミンCからなる組成物。
- ケルセチン、ビタミンB3、およびビタミンCの重量比が、1:0.02〜1:0.2〜2.5であることを特徴とする、請求項12に記載の組成物。
- 前記重量比が、1:0.05〜0.2:0.5〜1である請求項13に記載の組成物。
- 前記重量比が、1:0.1〜0.2:0.5〜1である請求項13に記載の組成物。
- 前記重量比が、1:0.04:1である請求項13に記載の組成物。
- 前記重量比が、1:0.08:1である請求項13に記載の組成物。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80760106P | 2006-07-17 | 2006-07-17 | |
US60/807,601 | 2006-07-17 | ||
US80769406P | 2006-07-18 | 2006-07-18 | |
US60/807,694 | 2006-07-18 | ||
US90062607P | 2007-02-08 | 2007-02-08 | |
US60/900,626 | 2007-02-08 | ||
US91174707P | 2007-04-13 | 2007-04-13 | |
US60/911,747 | 2007-04-13 | ||
US91316407P | 2007-04-20 | 2007-04-20 | |
US60/913,164 | 2007-04-20 | ||
PCT/US2007/073578 WO2008011363A2 (en) | 2006-07-17 | 2007-07-16 | Quercetin-containing compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009543883A JP2009543883A (ja) | 2009-12-10 |
JP5254227B2 true JP5254227B2 (ja) | 2013-08-07 |
Family
ID=38957518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009520941A Expired - Fee Related JP5254227B2 (ja) | 2006-07-17 | 2007-07-16 | ケルセチン含有組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US7745486B2 (ja) |
EP (1) | EP2040708B1 (ja) |
JP (1) | JP5254227B2 (ja) |
TW (1) | TWI451846B (ja) |
WO (1) | WO2008011363A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202900B2 (en) | 2007-10-01 | 2012-06-19 | Quercegen Pharmaceuticals Llc | Method for stabilizing quercetin |
US8680053B2 (en) * | 2008-07-09 | 2014-03-25 | Quercegen Pharmaceuticals Llc | Improving renal function with quercetin-containing compositions |
US8574619B2 (en) * | 2008-09-05 | 2013-11-05 | Quercegen Pharmaceuticals, LLC | Reducing cholesterol levels with combined use of quercetin and statin |
WO2010062681A2 (en) | 2008-10-30 | 2010-06-03 | University Of South Florida | Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism |
CN102215698A (zh) * | 2008-11-21 | 2011-10-12 | 花王株式会社 | 精制绿茶提取物 |
US20110223256A1 (en) * | 2010-03-11 | 2011-09-15 | Stokely-Van Camp, Inc. | Method For Stabilizing Flavonoid Aqueous Dispersion |
US20130052162A1 (en) * | 2010-04-20 | 2013-02-28 | Cedars-Sinai Medical Center | Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon |
BR112013001312A2 (pt) * | 2010-07-20 | 2018-01-23 | Itt Mfg Enterprises Llc | método de fixação melhorada para impulsor |
WO2012018597A2 (en) * | 2010-07-26 | 2012-02-09 | Chemotherapeutics, Llc | Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments |
CN103813723B (zh) | 2011-06-06 | 2017-03-15 | 荷兰联合利华有限公司 | 可食用组合物 |
JP6082737B2 (ja) * | 2011-07-07 | 2017-02-15 | リサーチ キャンサー インスティテュート オブ アメリカResearch Cancer Institute Of America | がんを治療するためのシステム、方法、および製剤 |
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
US10391096B2 (en) | 2011-10-13 | 2019-08-27 | Quercegen Pharmaceuticals Llc | Method for treating thrombotic disorders using quercetin-containing compositions |
US20130129680A1 (en) * | 2011-11-23 | 2013-05-23 | Thomas Christian Lines | Method for treating hepatitis c virus infection using quercetin-containing compositions |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9101580B2 (en) * | 2012-12-18 | 2015-08-11 | Matthew Bennett | Compositions and methods for treating traumatic brain injury |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
KR101640284B1 (ko) * | 2013-05-09 | 2016-07-15 | 가톨릭대학교 산학협력단 | 메트포민과 퀘르세틴을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물 |
KR101531937B1 (ko) * | 2013-08-01 | 2015-07-06 | 한국기초과학지원연구원 | 퀘르세틴을 유효성분으로 하는 어류의 항바이러스 조성물 |
DE102014209390A1 (de) * | 2014-05-19 | 2015-11-19 | Rogama Bv | Lastenaufnahmeträger |
US20170360815A1 (en) | 2016-02-25 | 2017-12-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
EP3465212A4 (en) | 2016-05-23 | 2020-01-08 | California Institute of Technology | REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
KR102418100B1 (ko) * | 2016-10-18 | 2022-07-08 | (주)아모레퍼시픽 | 신규한 퀘르세틴계 화합물을 포함하는 인지기능 개선용 조성물 |
WO2018157081A1 (en) | 2017-02-27 | 2018-08-30 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2018213204A1 (en) * | 2017-05-15 | 2018-11-22 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
US10987371B2 (en) | 2017-06-09 | 2021-04-27 | Adaerata, Limited Partnership | Methods of preventing or treating filovirus and flavivirus diseases |
JP7410055B2 (ja) * | 2018-06-21 | 2024-01-09 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | ニコチンアミドアデニンジヌクレオチド(nad+)前駆体及び少なくとも1種のケトン又はケトン前駆体を使用する組成物及び方法 |
GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
CA3121235A1 (en) | 2018-11-30 | 2020-06-04 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for reducing major thrombotic events in cancer patients |
US20200197355A1 (en) * | 2018-12-20 | 2020-06-25 | Public Joint Stock Company "Scientific Industrial Centre "Borshchahivskiy Chemical-Pharmaceutical Pl | Methods, compositions and containers for reducing solid form quercetin degradation and 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid toxic byproducts thereof |
US20200197354A1 (en) * | 2018-12-20 | 2020-06-25 | Public Joint Stock Company "Scientific Industrial Centre "Borshchahivskiy Chemical- Pharmaceutical P | Methods, compositions and containers for reducing solid form quercetin degradation and 2,4,6-trihydroxybenzoic acid toxic byproduct thereof |
US11156623B2 (en) | 2018-12-20 | 2021-10-26 | Public Joint Stock Company “Scientific Industrial Centre Borshchahivskiy Chemical-Pharmaceutical Plant” | Methods of monitoring safety of quercetin compositions |
KR20210126519A (ko) * | 2020-04-09 | 2021-10-20 | 권두한 | 항코로나바이러스능을 가지는 플라보노이드 배당체 |
IT202000022759A1 (it) * | 2020-09-28 | 2022-03-28 | Euro Pharma Srl | Composizione di combinazione ad attività antivirale e di interazione con sars-cov-2 |
JP2023550994A (ja) * | 2020-11-27 | 2023-12-06 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | Covid-19及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物 |
CN117999074A (zh) * | 2021-05-19 | 2024-05-07 | 奎尔塞斯制药股份公司 | 用于治疗肌萎缩侧索硬化症的含有槲皮素的组合物 |
US20230029216A1 (en) * | 2021-07-16 | 2023-01-26 | Beth Israel Deaconess Medical Center, Inc. | Method for treating sickle cell disease using quercetin-containing compositions |
WO2024101207A1 (ja) * | 2022-11-07 | 2024-05-16 | サントリーホールディングス株式会社 | ケルセチン又はその配糖体を含有する認知機能の低下抑制又は改善用組成物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US5026721A (en) | 1989-06-05 | 1991-06-25 | Dudrick Stanley J | Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition |
US5948443A (en) | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
CA2284290A1 (en) * | 1997-03-20 | 1998-09-24 | Samuel Russell Vester | Nutritional supplement for cardiovascular health |
AT407942B (de) | 1997-04-16 | 2001-07-25 | Husz Georg Bela | Getränk, konzentrat-kombination sowie verfahren zur herstellung eines getränkes |
US5846569A (en) | 1997-06-20 | 1998-12-08 | Creative Labs, Inc. | Colostrum supplement |
DE19809304A1 (de) | 1998-03-05 | 1999-09-09 | Merck Patent Gmbh | Formulierungen mit antiviraler Wirkung |
WO2000012085A1 (en) | 1998-08-27 | 2000-03-09 | Merck Patent Gmbh | Ascorbate-isoquercetin compositions |
US6277426B1 (en) | 1998-09-18 | 2001-08-21 | Swiss Alpine Power, Inc. | Dairy product and process for making |
US6261589B1 (en) | 1999-03-02 | 2001-07-17 | Durk Pearson | Dietary supplement nutrient soft drink composition with psychoactive effect |
AU3287200A (en) | 1999-03-16 | 2000-10-04 | Merck Patent Gmbh | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
US6210701B1 (en) | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
US6299925B1 (en) | 1999-06-29 | 2001-10-09 | Xel Herbaceuticals, Inc. | Effervescent green tea extract formulation |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6579544B1 (en) | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
JP2002051732A (ja) * | 2000-06-12 | 2002-02-19 | Access Business Group Llc | 食事による植物性化学物質欠乏症を矯正する組成物及び方法 |
AU2001277940A1 (en) | 2000-07-20 | 2002-02-05 | Bradford D. Pitman | Dietary supplement compositions |
ITBS20010027A1 (it) * | 2001-03-23 | 2002-09-23 | Gen Topics Srl | Principio attivo a base di acido lipoico ed acidi grassi polienolici |
US6680342B2 (en) | 2001-09-20 | 2004-01-20 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
US20030068391A1 (en) * | 2001-10-04 | 2003-04-10 | Harris Dennis H. | Ingestible nerve and circulatory nutritional formulation |
US6551629B1 (en) | 2002-07-03 | 2003-04-22 | Vitacost.Com, Inc. | Cardiovascular promotion and maintenance composition |
ES2322577T3 (es) * | 2002-10-23 | 2009-06-23 | Quercegen Holdings Llc | Composiciones antioxidantes. |
US6821536B2 (en) | 2002-11-22 | 2004-11-23 | Quercegen Holdings Llc | Antioxidative compositions |
US20040126461A1 (en) * | 2002-10-23 | 2004-07-01 | Lines Thomas Christian | Composition for enhancing physical performance |
US7270840B2 (en) | 2002-11-22 | 2007-09-18 | New Sun Nutrition Llc | Antioxidative compositions |
US7569239B2 (en) * | 2002-11-22 | 2009-08-04 | The Frs Company | Antioxidative compositions |
-
2007
- 2007-07-16 EP EP07799611.4A patent/EP2040708B1/en active Active
- 2007-07-16 US US11/778,234 patent/US7745486B2/en active Active
- 2007-07-16 WO PCT/US2007/073578 patent/WO2008011363A2/en active Application Filing
- 2007-07-16 JP JP2009520941A patent/JP5254227B2/ja not_active Expired - Fee Related
- 2007-07-17 TW TW096125955A patent/TWI451846B/zh not_active IP Right Cessation
-
2009
- 2009-12-16 US US12/639,212 patent/US8440704B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2040708A4 (en) | 2011-04-20 |
TW200816934A (en) | 2008-04-16 |
WO2008011363A3 (en) | 2008-09-18 |
EP2040708B1 (en) | 2018-03-14 |
EP2040708A2 (en) | 2009-04-01 |
US7745486B2 (en) | 2010-06-29 |
US20100160245A1 (en) | 2010-06-24 |
TWI451846B (zh) | 2014-09-11 |
JP2009543883A (ja) | 2009-12-10 |
US20080015247A1 (en) | 2008-01-17 |
WO2008011363A2 (en) | 2008-01-24 |
US8440704B2 (en) | 2013-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5254227B2 (ja) | ケルセチン含有組成物 | |
US8901109B2 (en) | Quercetin-containing compositions | |
CN108778269B (zh) | 包含烟碱酰胺核糖苷和尿石素的组合物 | |
JP6803915B2 (ja) | 睡眠障害改善剤及び睡眠障害の改善方法 | |
JP6545256B2 (ja) | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 | |
JP5587780B2 (ja) | フコキサンチン又はこれを含有する海藻類抽出物を含有する脂質代謝性疾患の予防又は治療用組成物 | |
JP2011157366A (ja) | 身体能力向上のための組成物 | |
RU2530769C2 (ru) | Снижение уровней холестерина путем совместного применения кверцетина и статина | |
JP2014533729A (ja) | ケルセチンを含有するc型肝炎ウイルスの感染を治療するための医薬品 | |
KR101597781B1 (ko) | 락토바실러스 브레비스 g-101 및 이의 용도 | |
JP2005185188A (ja) | アセロラ処理物およびl−カルニチン含有組成物 | |
CN101505748A (zh) | 含斛皮素组合物 | |
JP7137483B2 (ja) | アンモニア代謝促進剤 | |
JP2009107987A (ja) | 筋力向上剤 | |
EP3389666A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
JP2022135271A (ja) | 血中トリグリセリド濃度上昇抑制剤 | |
WO2018225167A1 (ja) | アンモニア代謝促進剤 | |
JP2009007256A (ja) | Nadh/nadphオキシダーゼ抑制剤 | |
JP2009023948A (ja) | ドーパミン抑制剤 | |
JP2014152117A (ja) | 免疫賦活剤 | |
KR20120096328A (ko) | 퀘르세틴을 유효성분으로 포함하는 비알콜성 지방간의 예방 또는 치료용 조성물 | |
WO2013118136A1 (en) | Stable taurine oral composition | |
JP2012077007A (ja) | 持久力向上剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120918 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130117 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130417 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |